Cetuximab in combination therapy: From bench to clinic

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Cetuximab, a chimeric IgG1 monoclonal antibody directed against the ligand-binding domain of the epidermal growth factor receptor, offers a paradigm for the combination of molecularly targeted therapies with cytotoxic agents. In preclinical models, the addition of cetuximab to chemotherapy or radiation therapy enhances antitumor activity. Proposed mechanisms include reducing tumor cell proliferation, angiogenesis, and DNA repair capacity; increasing apoptosis; and inducing cell cycle arrest at treatment-sensitive points. These effects may enhance and restore tumor sensitivity to cytotoxic therapies. In clinical trials, the addition of cetuximab to chemotherapy improves outcomes of patients who had previously failed such agents, as illustrated in irinotecan-resistant and oxaliplatin-refractory metastatic colorectal cancer. As initial therapy, the addition of cetuximab to chemotherapy extends survival in colorectal cancer, lung cancer, and head and neck cancer. Combining cetuximab with radiation therapy extends survival in locally advanced head and neck cancer. As predictive biomarkers are identified, it may become possible to select patients most likely to benefit from such combinations.

Original languageEnglish (US)
Pages (from-to)171-180
Number of pages10
JournalCancer and Metastasis Reviews
Volume29
Issue number1
DOIs
StatePublished - Mar 2010

Fingerprint

Head and Neck Neoplasms
irinotecan
oxaliplatin
Drug Therapy
Colorectal Neoplasms
Lung Neoplasms
Radiotherapy
Therapeutics
Survival
Cytotoxins
Cell Cycle Checkpoints
Epidermal Growth Factor Receptor
DNA Repair
Neoplasms
Immunoglobulin G
Biomarkers
Monoclonal Antibodies
Cell Proliferation
Cetuximab
Clinical Trials

Keywords

  • Cetuximab
  • Colorectal cancer
  • Head and neck cancer
  • Lung cancer
  • Monoclonal antibodies
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cetuximab in combination therapy : From bench to clinic. / Gerber, David E.; Choy, Hak.

In: Cancer and Metastasis Reviews, Vol. 29, No. 1, 03.2010, p. 171-180.

Research output: Contribution to journalArticle

@article{76b8812012384f3db65ff225b30ab57f,
title = "Cetuximab in combination therapy: From bench to clinic",
abstract = "Cetuximab, a chimeric IgG1 monoclonal antibody directed against the ligand-binding domain of the epidermal growth factor receptor, offers a paradigm for the combination of molecularly targeted therapies with cytotoxic agents. In preclinical models, the addition of cetuximab to chemotherapy or radiation therapy enhances antitumor activity. Proposed mechanisms include reducing tumor cell proliferation, angiogenesis, and DNA repair capacity; increasing apoptosis; and inducing cell cycle arrest at treatment-sensitive points. These effects may enhance and restore tumor sensitivity to cytotoxic therapies. In clinical trials, the addition of cetuximab to chemotherapy improves outcomes of patients who had previously failed such agents, as illustrated in irinotecan-resistant and oxaliplatin-refractory metastatic colorectal cancer. As initial therapy, the addition of cetuximab to chemotherapy extends survival in colorectal cancer, lung cancer, and head and neck cancer. Combining cetuximab with radiation therapy extends survival in locally advanced head and neck cancer. As predictive biomarkers are identified, it may become possible to select patients most likely to benefit from such combinations.",
keywords = "Cetuximab, Colorectal cancer, Head and neck cancer, Lung cancer, Monoclonal antibodies, Targeted therapy",
author = "Gerber, {David E.} and Hak Choy",
year = "2010",
month = "3",
doi = "10.1007/s10555-010-9215-6",
language = "English (US)",
volume = "29",
pages = "171--180",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Cetuximab in combination therapy

T2 - From bench to clinic

AU - Gerber, David E.

AU - Choy, Hak

PY - 2010/3

Y1 - 2010/3

N2 - Cetuximab, a chimeric IgG1 monoclonal antibody directed against the ligand-binding domain of the epidermal growth factor receptor, offers a paradigm for the combination of molecularly targeted therapies with cytotoxic agents. In preclinical models, the addition of cetuximab to chemotherapy or radiation therapy enhances antitumor activity. Proposed mechanisms include reducing tumor cell proliferation, angiogenesis, and DNA repair capacity; increasing apoptosis; and inducing cell cycle arrest at treatment-sensitive points. These effects may enhance and restore tumor sensitivity to cytotoxic therapies. In clinical trials, the addition of cetuximab to chemotherapy improves outcomes of patients who had previously failed such agents, as illustrated in irinotecan-resistant and oxaliplatin-refractory metastatic colorectal cancer. As initial therapy, the addition of cetuximab to chemotherapy extends survival in colorectal cancer, lung cancer, and head and neck cancer. Combining cetuximab with radiation therapy extends survival in locally advanced head and neck cancer. As predictive biomarkers are identified, it may become possible to select patients most likely to benefit from such combinations.

AB - Cetuximab, a chimeric IgG1 monoclonal antibody directed against the ligand-binding domain of the epidermal growth factor receptor, offers a paradigm for the combination of molecularly targeted therapies with cytotoxic agents. In preclinical models, the addition of cetuximab to chemotherapy or radiation therapy enhances antitumor activity. Proposed mechanisms include reducing tumor cell proliferation, angiogenesis, and DNA repair capacity; increasing apoptosis; and inducing cell cycle arrest at treatment-sensitive points. These effects may enhance and restore tumor sensitivity to cytotoxic therapies. In clinical trials, the addition of cetuximab to chemotherapy improves outcomes of patients who had previously failed such agents, as illustrated in irinotecan-resistant and oxaliplatin-refractory metastatic colorectal cancer. As initial therapy, the addition of cetuximab to chemotherapy extends survival in colorectal cancer, lung cancer, and head and neck cancer. Combining cetuximab with radiation therapy extends survival in locally advanced head and neck cancer. As predictive biomarkers are identified, it may become possible to select patients most likely to benefit from such combinations.

KW - Cetuximab

KW - Colorectal cancer

KW - Head and neck cancer

KW - Lung cancer

KW - Monoclonal antibodies

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77349118230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77349118230&partnerID=8YFLogxK

U2 - 10.1007/s10555-010-9215-6

DO - 10.1007/s10555-010-9215-6

M3 - Article

C2 - 20140759

AN - SCOPUS:77349118230

VL - 29

SP - 171

EP - 180

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 1

ER -